{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:33:49Z","timestamp":1787787229866,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.005","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:25:47Z","timestamp":1771331147000},"page":"179-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early-Stage Hodgkin Lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Kishan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.hoc.2025.12.005_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.005_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"Calgb 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.005_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term Follow-Up of the response-adjusted therapy for advanced hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.005_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.005_bib5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.005_bib6","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.005_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.005_bib8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2025.12.005_bib9","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.hoc.2025.12.005_bib10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.005_bib11","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","volume":"1","author":"Aldin","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.005_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-Term Follow-Up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2025.12.005_bib13","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.005_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.12.005_bib15","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/10428194.2022.2107204","article-title":"Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory\/relapsed Hodgkin lymphoma: a lymphoma study association phase I\/II study","volume":"63","author":"Stamatoullas","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.005_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.005_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-Year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.005_bib18","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.005_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.005_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.hoc.2025.12.005_bib21","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.005_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10450","key":"10.1016\/j.hoc.2025.12.005_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.005_bib24","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.005_bib25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2025.12.005_bib26","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.005_bib27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Brockelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.005_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.12.005_bib29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2024-200992","article-title":"Updated analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and dacarbazine for nonbulky, early-stage classical hodgkin lymphoma","volume":"144","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.12.005_bib30","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.005_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.17073","volume":"193","author":"Gibb","year":"2021","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.hoc.2025.12.005_bib32","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >\/=60 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.005_bib33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.005_bib34","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"30","key":"10.1016\/j.hoc.2025.12.005_bib35","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential Brentuximab Vedotin and Doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.005_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of Nivolumab plus Doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin Lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.12.005_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890668.27643.97","article-title":"P025: RADAR: an international phase III, PET response-adapted, randomised trial in progress, comparing ABVD\u00b1ISRT with brentuximab vedotin+AVD\u00b1ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma","volume":"6","author":"Radford","year":"2022","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.005_bib38","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2023-189652","article-title":"AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.005_bib39","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:34Z","timestamp":1773955534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825001467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858825001467"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-Stage Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}